Eli Lilly Plans R&D Investment in China
Eli Lilly plans to invest $100 million in research and development in China over the next five years through Lilly Asian Ventures, a Lilly-owned venture capital firm that makes investments in Asia.
Indianapolis, IN (Nov. 14)-Eli Lilly plans to invest $100 million in research and development (R&D) in China over the next five years through Lilly Asian Ventures, a Lilly-owned venture capital firm that makes investments in Asia.
Lilly Asian Ventures was established in 2007 with a geographic focus on the emerging life-science businesses of east and south Asia, particularly China and India.
Earlier this year, Eli Lilly invested $10 million in BioVeda China (Shanghai), a venture capital fund focused on investment in the life-sciences in China.
In September 2007, Eli Lilly formed an R&D pact with Hutchison MediPharma (Shanghai) for the discovery and development of new clinical candidates in oncology and inflammation. Hutchison MediPharma will receive development milestone payments of $20–29 million per candidate and royalties upon commercialization of a candidate.
Eli Lilly also has a pact with Shanghai ChemExplorer (Shanghai), a contract research organization in China. The companies formed a collaborative R&D pact in 2002.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
PacBio Chosen as Tech Partner for Global Alzheimer’s Disease Research Project
April 23rd 2025The project, the North African Dementia Registry, will unite multiple entities for the purpose of developing a comprehensive dataset to advance the research community’s understanding of Alzheimer’s disease and other dementias in diverse populations.
